Navigation Links
UCSF brain tumor vaccine trial shows promising results

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.

Known as a glioma, this cancerous tumor is always fatal. Findings from a group of 12 study patients showed that vitespen vaccination (trademarked as Oncophage) was effective in stimulating the patient’s immune system to attack the tumor cells, a function that is known medically as tumor-specific immune response. All the patients had recurrent, high-grade glioma, and all showed the immune response. The vaccine is made from the patient’s own tumor.

The clinical trial was conducted by the UCSF Brain Tumor Research Center. Results were presented today (April 16) at the 75th annual meeting of the American Association of Neurological Surgeons in Washington, DC.

“In this trial, we have observed a correlation between immune response as a result of vitespen vaccination and potential clinical benefit,?said Andrew T. Parsa, MD, PhD, assistant professor in the Department of Neurological Surgery at UCSF and recipient of the 2007 Young Investigator Award at AANS. “We are encouraged by the prolonged improvement in overall survival rates, although this phase 1/2 study is not designed to primarily evaluate efficacy. The patients in this trial represent the most challenging patient population to treat.?

Of the 12 patients being treated, eight can currently be evaluated for overall survival, while four are still receiving treatment. Seven out of the eight patients have exceeded the historical median benchmark of 6.5 months survival from time of recurrence. The investigators will continue to follow the patients for overall survival. Based on these results, a larger, multi-center phase 2 study is planned for late 2007.

Derived from each individual’s tumor, vitespen contains the “fingerprint?of the patient’s particular cance
'"/>

Source:University of California - San Francisco


Page: 1 2 3

Related biology news :

1. Controversial drug shown to act on brain protein to cut alcohol use
2. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
3. Mouse brain tumors mimic those in human genetic disorder
4. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
5. First atlas of key brain genes could speed research on cancer, neurological diseases
6. NYU study reveals how brains immune system fights viral encephalitis
7. Stem cells from brain transformed to produce insulin at Stanford
8. Birds brains reveal source of songs
9. Loves all in the brain: fMRI study shows strong, lateralized reward, not sex, drive
10. Revolutionary nanotechnology illuminates brain cells at work
11. A puzzle piece found in unraveling the wiring of the brain
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCSF brain tumor vaccine trial shows promising results

(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... 16, 2014 Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... Chemical Sensor Market 2015-2019" report to their offering. ... One major trend upcoming in this market is the ... sensors help in recording of patient data for quick ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... new bacterium in an immune-compromised patient, according to a ... belongs to the family Acetobacteraceae and includes bacteria common ... industry, such as vinegar-making. "This is the first ... of the Acetobacteraceae," according to the article. ...
... single atom from the molecular structure of vancomycin aglycon, ... cell wall synthesis, significantly increasing the drug's spectrum of ... common strains of enterococci have become resistant to vancomycin ... This re-engineering effort could help make the drug more ...
... flu is bad enough for healthy people, but the ... weakened immune systems, such as patients on chemotherapy. A ... of Philadelphia will support research to determine how adults ... vulnerable to influenza, and will seek better ways to ...
Cached Biology News:Soil-bound prions that cause CWD remain infectious 2Scientists re-engineer a well-known antibiotic to counter drug resistance 2How can we protect patients with weakened immune systems from influenza? 2How can we protect patients with weakened immune systems from influenza? 3
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
(Date:12/24/2014)... December 23, 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide continued ... upgrades. This webinar series demonstrates online communication features ... leverage web conferencing’s most innovative and powerful tools. ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
...   Hospitals, health systems to benefit,from ... and other,performance management solutions Elsevier ... products,and services, has struck an exclusive partnership with ... learning solutions for process,improvement. Elsevier will market ...
... carbon, has the potential to make consumer electronic devices ... shrinking scale of electronics, also make graphene difficult to ... In September 2010, a UCLA research team ... and were able to fabricate graphene transistors with unparalleled ...
... 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ) ... agreements with various institutional investors and its CEO for ... in a registered direct offering at $8.85 per share, ... of the offering, before deducting expenses, are expected to ...
Cached Biology Technology:Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 2Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 3Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2Pharmacyclics Announces Results of Registered Direct Offering 2Pharmacyclics Announces Results of Registered Direct Offering 3
... provides a genome-wide microRNA (miRNA) expression profiling ... design, which enable highly sensitive and specific ... standard arrays for mature miRNA of all ... the Sanger miRBase database (Release 8.2). Our ...
... Microarrays designed for immunological studies, vaccine ... the flexible and powerful Paraflo microfluidic ... available as part of our comprehensive ... Custom Probe Content Probe content ...
... Custom peptide microarrays designed for ... serum samples and built on the ... platform. Thousands of customer specified sequences ... Sciences can provide assistance with custom ...
... the first time, you can identify and ... efficiently without interferences. The Agilent Multiple Affinity ... multiple high-abundant proteins from human serum, plasma, ... one device. With this revolutionary system, you ...
Biology Products: